➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Merck
McKesson
Dow
AstraZeneca

Last Updated: May 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Monomethyl fumarate


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Monomethyl fumarate?

Monomethyl fumarate is an investigational drug.

There have been 6 clinical trials for Monomethyl fumarate. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.

The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Biogen, Multiple Sclerosis Center of Northeastern New York, and Alkermes, Inc.

There are seven US patents protecting this investigational drug and thirty-three international patents.

Recent Clinical Trials for Monomethyl fumarate
TitleSponsorPhase
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy VolunteersBanner Life Sciences LLCPhase 1
Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008Almirall, S.A.Phase 1
Pharmacokinetics of DMF and the Effects of DMF on Exploratory BiomarkersBiogenPhase 4

See all Monomethyl fumarate clinical trials

Clinical Trial Summary for Monomethyl fumarate

Top disease conditions for Monomethyl fumarate
Top clinical trial sponsors for Monomethyl fumarate

See all Monomethyl fumarate clinical trials

US Patents for Monomethyl fumarate

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Monomethyl fumarate   Start Trial Triterpenes having human antifungal and antiyeast activity Naturtek, LLC (Duluth, MN)   Start Trial
Monomethyl fumarate   Start Trial Triterpenes having antibacterial activity Regents of the University of Minnesota (Minneapolis, MN)   Start Trial
Monomethyl fumarate   Start Trial Renin inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Monomethyl fumarate   Start Trial Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use XenoPort, Inc. (Santa Clara, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Monomethyl fumarate

Drugname Country Document Number Estimated Expiration Related US Patent
Monomethyl fumarate Australia 9495301 2020-09-29   Start Trial
Monomethyl fumarate Canada 2424013 2020-09-29   Start Trial
Monomethyl fumarate European Patent Office 1322661 2020-09-29   Start Trial
Monomethyl fumarate Japan 2004509972 2020-09-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Harvard Business School
Mallinckrodt
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.